Behbahani Ali Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
12
Insider Buys Sum
$181.81M
Insider Sells Quantity
1
Insider Sells Sum
$3,000.48

Insider Activity of Behbahani Ali

According to the SEC Form 4 filings, Behbahani Ali, being in a position of

  1. director at CRISPR Therapeutics AG,
    оver the last 12 months, has bought 0 shares, and sold 13679 shares for $780,935,
    over all time since 2026-09-17, has bought 0 shares, and sold 13679 shares for $780,935.

Biography of Behbahani Ali

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $780,9351100

Comparison of Insiders on Amount of Buys and Sells

2026-09-17SaleCRISPR Therapeutics AG
CRSP
director
13,679
0.0141%
$57.09$780,935-8.68%
2023-07-17PurchaseSavara Inc.
SVRA
10 percent owner
333,333
0.2084%
$3.00$999,999+32.8%
2023-07-05PurchaseBlack Diamond Therapeutics, Inc.
BDTX
director
1M
2.8199%
$5.00$5M-25.62%
2021-10-18PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
1.85M
11.1305%
$1.62$3M+63.35%
2021-06-28PurchaseMonte Rosa Therapeutics, Inc.
GLUE
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-03-16PurchaseMarker Therapeutics, Inc.
MRKR
10 percent owner
5.71M
9.5207%
$1.75$10M-4.3%
2020-04-03SaleTrevi Therapeutics, Inc.
TRVI
10 percent owner
1,128
0.0062%
$2.66$3,000+19.07%
2020-02-03PurchaseBlack Diamond Therapeutics, Inc.
BDTX
director
1.6M
3.3756%
$19.00$30.4M-15.11%
2019-07-22PurchaseMirum Pharmaceuticals, Inc.
MIRM
10 percent owner
900,000
5.3814%
$15.00$13.5M+5.09%
2019-05-09PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
5M
34.6117%
$10.00$50M-42.9%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.